MCID: KRT001
MIFTS: 63

Keratoconjunctivitis Sicca

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

MalaCards integrated aliases for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 72 49 28 51 41 14 69
Keratitis Sicca 49 69
Xerophthalmia 49 69
Dry Eye Syndromes 69
Dry Eye Syndrome 49
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 41 D007638

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to dry eye syndrome and keratoconjunctivitis, and has symptoms including dryness of eye, dacryops and eye manifestations. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and testes, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 72 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 dry eye syndrome 33.5 IL6 LTF NGF TNF
2 keratoconjunctivitis 31.5 CD79A IL4 NGF TLR9 TNF
3 chronic graft versus host disease 30.7 ALB CD79A IL1A
4 corneal disease 30.4 IL1A NGF TLR9
5 uveitis 30.4 IL1A IL4 TNF
6 leprosy 3 30.3 CD79A IL4 TNF
7 keratitis, hereditary 29.5 IL1B TLR4 TLR9
8 arthritis 29.4 IL1A IL1B IL6 TNF
9 graft-versus-host disease 29.3 IL1A IL1B IL6 TNF
10 juvenile rheumatoid arthritis 29.1 IL1B IL6 TNF
11 peritonitis 28.9 ALB IL1B IL6 TNF
12 chlamydia 28.6 CD79A IL1B IL6 TLR4 TNF
13 rheumatoid arthritis 28.5 CD79A IL1A IL1B IL4 IL6 TLR4
14 pneumonia 28.5 IL1B IL6 TLR4 TLR9 TNF
15 autoimmune disease 28.3 CD79A IL1B IL4 IL6 TLR9 TNF
16 colitis 28.2 IL1B IL4 IL6 TLR4 TLR9 TNF
17 otitis media 27.9 ALB CD79A IL1B IL4 IL6 TLR4
18 xerophthalmia 12.6
19 sjogren syndrome 12.1
20 myelopathy, htlv-1-associated 11.2
21 aplasia of lacrimal and salivary glands 11.2
22 tropical spastic paraparesis 11.2
23 retrovirus-associated myelopathy 11.2
24 cork-handlers' disease 10.6 ALB CD79A
25 ostertagiasis 10.6 ALB CD79A
26 dermatitis, atopic, 3 10.6 ALB CD79A
27 neuroschistosomiasis 10.5 CD79A NGF
28 congenital hypogammaglobulinemia 10.5 CD79A IL1A IL4
29 root caries 10.5 ALB CD79A LTF
30 parotitis 10.5 ALB CD79A LTF
31 tropical endomyocardial fibrosis 10.5 IL4 TNF
32 immunoglobulin a deficiency 1 10.5 CD79A IL4
33 hyperglobulinemic purpura 10.4 CD79A HSPG2
34 ocular cicatricial pemphigoid 10.4 CD79A IL4 NGF
35 tungiasis 10.4 IL4 TNF
36 endomyocardial fibrosis 10.4 IL4 TNF
37 nasal cavity disease 10.3 CD79A IL4 TLR9
38 tetanus 10.3 ALB CD79A IL4
39 autoimmune disease of urogenital tract 10.3 ALB CD79A TLR9
40 orofacial granulomatosis 10.3 CD79A IL4 TNF
41 dysentery 10.3 ALB CD79A IL1A LTF
42 pneumocystosis 10.3 ALB CD79A TNF
43 guillain-barre syndrome 10.3 ALB CD79A TNF
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
45 bronchitis 10.2 ALB CD79A TNF
46 skin conditions 10.2 IL1A TNF
47 progesterone-receptor negative breast cancer 10.2 ERBB2 TLR4
48 orthostatic proteinuria 10.2 ALB CD79A
49 hypersensitivity reaction type iv disease 10.2 CD79A TLR9 TNF
50 transient arthritis 10.2 ALB IL1A IL6

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


dryness of eye, dacryops, eye manifestations

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 IL1B LTF IL4 NGF IL6 TLR4
2 immune system MP:0005387 10.3 IL1B LTF IL4 NRTN IL6 TLR4
3 hematopoietic system MP:0005397 10.27 IL1B LTF IL4 IL6 IL1A CD79A
4 cellular MP:0005384 10.26 IL6 LTF IL4 ALB ERBB3 CD79A
5 cardiovascular system MP:0005385 10.24 IL1B NGF IL6 IL1A ERBB3 HSPG2
6 digestive/alimentary MP:0005381 10.21 IL4 NRTN IL6 ALB ERBB3 HSPG2
7 mortality/aging MP:0010768 10.15 IL6 IL1B NGF IL4 ERBB2 ALB
8 integument MP:0010771 10.13 IL1B IL4 NGF IL6 IL1A ERBB3
9 liver/biliary system MP:0005370 10.01 LTF IL4 IL6 ALB CD79A HSPG2
10 muscle MP:0005369 9.97 NGF NRTN IL6 ALB ERBB3 HSPG2
11 neoplasm MP:0002006 9.96 IL1B LTF IL6 TLR4 ALB ERBB3
12 nervous system MP:0003631 9.9 IL6 IL1B IL4 NGF NRTN ERBB3
13 normal MP:0002873 9.56 LTF NGF IL4 ERBB2 ALB ERBB3
14 respiratory system MP:0005388 9.17 IL6 IL4 ERBB2 ERBB3 HSPG2 TNF

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
3
Povidone Approved Phase 4 9003-39-8
4
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90-82-4 7028
7
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
8
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Loteprednol Approved Phase 4,Phase 3,Phase 2 129260-79-3, 82034-46-6 9865442 444025
11
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
12
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
13
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
14
Ethanol Approved Phase 4,Phase 2 64-17-5 702
15
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
16
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
17
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
24
Timolol Approved Phase 4,Phase 3 26839-75-8 5478 33624
25
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
26
Travoprost Approved Phase 4 157283-68-6 5282226
27
Pilocarpine Approved, Investigational Phase 4 92-13-7, 54-71-7 5910
28
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
29
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
30
Sulfacetamide Approved Phase 4 144-80-9 5320
31
Tobramycin Approved, Investigational Phase 4,Phase 1 32986-56-4 36294 5496
32
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
33
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
34
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
36
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
37
Sorbitol Approved Phase 4 50-70-4 5780
38
Dimenhydrinate Approved Phase 4 523-87-5 441281
39
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
40
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
41
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
42 Tocopherol Approved, Investigational, Nutraceutical Phase 4
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
46
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
47 Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4
48
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
49 tannic acid Approved, Nutraceutical Phase 4
50 Gallopamil Investigational Phase 4 16662-47-8

Interventional clinical trials:

(show top 50) (show all 745)

# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
8 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
9 Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance Unknown status NCT01589640 Phase 4
10 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
11 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
12 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
13 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
14 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
15 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
16 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
17 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4 Lotemax;Artificial Tears
18 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
19 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
20 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
21 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
22 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
23 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
24 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
25 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
26 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
27 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
28 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
29 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
30 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
31 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
32 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
33 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
34 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
35 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
36 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
37 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
38 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
39 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
40 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
41 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
42 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
43 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
44 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
45 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
46 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
47 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
48 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
49 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
50 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

# Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 28

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

38
Eye, Salivary Gland, Testes, Thyroid, B Cells, Bone, Neutrophil

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 348)
# Title Authors Year
1
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
2
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
3
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
4
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
5
Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca. ( 29038779 )
2017
6
Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. ( 28218751 )
2017
7
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2017
8
Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits. ( 29038781 )
2017
9
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
10
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
11
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
12
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
13
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
14
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
15
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2016
16
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
17
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2016
18
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
19
Assessment of tear film osmolarity using the TearLab(a8c) osmometer in normal dogs and dogs with keratoconjunctivitis sicca. ( 27761982 )
2016
20
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
21
Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. ( 25747049 )
2015
22
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. ( 26628876 )
2015
23
Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. ( 26466228 )
2015
24
Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. ( 25675975 )
2015
25
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. ( 25664315 )
2015
26
Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. ( 25802852 )
2015
27
Salivary gland scintigraphy in patients suffering from severe keratoconjunctivitis sicca. Evaluation of the viability of submandibular glands before and after transfer into the temporal fossa. ( 26083667 )
2015
28
The Role of Chlamydia Pneumoniae in the Etiology Keratoconjunctivitis Sicca (KCS). ( 25395268 )
2014
29
Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology. ( 25378890 )
2014
30
Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in SjAPgren syndrome patients with or without punctal occlusions. ( 24977983 )
2014
31
Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca. ( 24395332 )
2014
32
Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study. ( 24799029 )
2014
33
Uveodermatologic syndrome concurrent with keratoconjunctivitis sicca in a miniature poodle dog. ( 24891645 )
2014
34
Retrospective study of the prevalence of keratoconjunctivitis sicca in diabetic and nondiabetic dogs after phacoemulsification. ( 25429857 )
2014
35
Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits. ( 23514268 )
2013
36
Corneal sequestrum in a dog with chronic unilateral keratoconjunctivitis sicca. ( 24299547 )
2013
37
Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. ( 23884332 )
2013
38
Infrared ocular thermography in dogs with and without keratoconjunctivitis sicca. ( 23905697 )
2013
39
A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs. ( 22853450 )
2013
40
Bilateral parotid duct transposition for keratoconjunctivitis sicca in a Connemara stallion. ( 23067239 )
2013
41
Punctal plugs versus artificial tears for treating primary SjAPgren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function. ( 23649850 )
2013
42
Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. ( 23813419 )
2013
43
Proteomic analysis of secretion from human transplanted submandibular gland replacing lacrimal gland with severe keratoconjunctivitis sicca. ( 22306964 )
2012
44
Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis in 25 Cavalier King Charles spaniel dogs. Part I: clinical signs, histopathology, and inheritance. ( 22212237 )
2012
45
Canine neurogenic Keratoconjunctivitis sicca: 11 cases (2006-2010). ( 22051024 )
2012
46
Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis in Cavalier King Charles spaniel dogs. Part II: candidate gene study. ( 22339941 )
2012
47
An experimental study of the management of severe keratoconjunctivitis sicca with autologous reduced-sized submandibular gland transplantation. ( 22051179 )
2012
48
Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. ( 22041848 )
2012
49
Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs. ( 25653763 )
2012
50
Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjogren's syndrome. ( 21558290 )
2012

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

Pathways related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CD79A ERBB2 ERBB3 IL1A IL1B IL4
2
Show member pathways
13.85 ERBB2 ERBB3 HSPG2 IL1A IL1B IL4
3
Show member pathways
13.7 ERBB2 ERBB3 IL1A IL1B IL4 IL6
4
Show member pathways
13.57 ERBB2 ERBB3 IL1A IL1B IL4 IL6
5
Show member pathways
13.41 ERBB2 ERBB3 IL1A IL1B IL4 IL6
6
Show member pathways
13.38 ERBB2 ERBB3 IL1A IL1B IL4 IL6
7
Show member pathways
13.33 ERBB2 IL1A IL1B IL4 IL6 NGF
8
Show member pathways
13.24 CD79A ERBB2 ERBB3 IL1A IL1B IL4
9
Show member pathways
13.01 IL1A IL1B IL6 TLR4 TLR9 TNF
10
Show member pathways
12.87 IL1A IL1B IL4 IL6 TNF
11
Show member pathways
12.84 IL1A IL1B IL4 IL6 TLR4 TLR9
12
Show member pathways
12.73 IL1A IL1B IL6 NGF TLR4 TLR9
13
Show member pathways
12.69 IL1A IL1B NGF TLR4 TLR9 TNF
14
Show member pathways
12.65 IL1A IL1B IL4 IL6 TLR4 TNF
15 12.62 CD79A IL1B IL4 TLR9 TNF
16
Show member pathways
12.59 IL1B IL6 TLR4 TLR9 TNF
17
Show member pathways
12.5 IL1A IL1B IL4 IL6 TNF
18
Show member pathways
12.46 ERBB2 ERBB3 IL1A IL1B
19
Show member pathways
12.4 ALB IL1B IL4 IL6 TNF
20 12.37 ERBB2 ERBB3 HSPG2 TLR4 TNF
21
Show member pathways
12.36 IL1B IL4 IL6 TNF
22
Show member pathways
12.34 IL1A IL6 TLR4 TLR9 TNF
23
Show member pathways
12.33 IL1A IL1B IL4 TLR4 TNF
24
Show member pathways
12.33 IL1A IL1B IL6 TLR4 TNF
25
Show member pathways
12.26 IL1A IL1B TLR4 TNF
26 12.24 IL1A IL1B IL6 NGF TNF
27 12.23 IL6 TLR4 TLR9 TNF
28
Show member pathways
12.22 IL1A IL1B IL4 IL6 TNF
29 12.22 IL1A IL1B IL6 TLR4 TLR9 TNF
30
Show member pathways
12.15 IL1B IL4 IL6 TLR4 TLR9 TNF
31 12.06 CD79A IL4 IL6 TNF
32 12.05 IL1A IL1B IL4 IL6 TNF
33
Show member pathways
11.99 IL1B IL6 TLR4 TLR9 TNF
34 11.98 IL1A IL1B IL6 TNF
35 11.97 IL1B IL6 TLR4 TNF
36
Show member pathways
11.97 ERBB2 ERBB3 IL1A IL1B TLR4 TLR9
37 11.93 IL1A IL1B IL4 IL6 TNF
38 11.92 ERBB2 IL6 TLR4
39 11.91 IL1A IL1B IL6 TLR4
40 11.9 CD79A HSPG2 IL6
41 11.89 IL1B TLR4 TNF
42
Show member pathways
11.88 IL1B IL4 IL6 TLR4 TLR9
43 11.86 IL1A IL1B IL6 TLR4 TNF
44 11.84 IL1B IL6 TLR9 TNF
45 11.81 IL1B IL4 TNF
46 11.81 IL1A IL1B IL4 IL6 TLR4 TNF
47 11.76 IL1A IL1B IL6 TLR4 TNF
48 11.75 IL1B IL4 IL6 TNF
49
Show member pathways
11.75 IL1A IL1B IL6 TNF
50 11.66 IL1B IL6 TLR4 TNF

GO Terms for Keratoconjunctivitis Sicca

Cellular components related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ALB ERBB3 HSPG2 IL1A IL1B IL4
2 extracellular region GO:0005576 9.4 ALB ERBB3 HSPG2 IL1A IL1B IL4

Biological processes related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.99 IL1A IL1B IL4 IL6 TLR4 TNF
2 regulation of receptor activity GO:0010469 9.98 IL1A IL1B IL4 IL6 NGF NRTN
3 cellular protein metabolic process GO:0044267 9.97 ALB HSPG2 IL6 LTF
4 defense response to bacterium GO:0042742 9.96 LTF TLR4 TLR9 TNF
5 inflammatory response GO:0006954 9.95 HSPG2 IL1A IL1B IL6 TLR4 TLR9
6 MAPK cascade GO:0000165 9.93 ERBB2 ERBB3 IL1B NRTN TNF
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 ERBB2 ERBB3 NGF NRTN
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.85 IL1B LTF TLR4 TLR9 TNF
9 positive regulation of T cell proliferation GO:0042102 9.81 IL1B IL4 IL6
10 humoral immune response GO:0006959 9.81 IL6 LTF TNF
11 defense response to Gram-negative bacterium GO:0050829 9.8 IL6 LTF TLR4 TLR9
12 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B TLR4 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 IL1B TLR4 TNF
14 positive regulation of JNK cascade GO:0046330 9.78 IL1B TLR4 TLR9 TNF
15 positive regulation of B cell proliferation GO:0030890 9.77 IL4 TLR4 TLR9
16 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.75 IL1A IL1B TNF
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 IL1B TLR4 TNF
18 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.73 ERBB3 IL1A IL1B
19 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.7 IL1B TNF
20 negative regulation of ERBB signaling pathway GO:1901185 9.7 ERBB2 ERBB3
21 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR4 TLR9
22 negative regulation of interleukin-6 production GO:0032715 9.7 TLR4 TLR9 TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL1B TNF
24 I-kappaB phosphorylation GO:0007252 9.69 TLR4 TLR9
25 regulation of cytokine secretion GO:0050707 9.69 TLR4 TLR9
26 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.68 IL1A IL1B
27 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.68 IL1A IL1B
28 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.68 IL1B TLR9
29 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
30 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
31 positive regulation of interleukin-8 production GO:0032757 9.67 IL1B TLR4 TLR9 TNF
32 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.66 TLR4 TNF
33 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
34 ectopic germ cell programmed cell death GO:0035234 9.65 IL1A IL1B
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 TLR4
36 positive regulation of interferon-beta biosynthetic process GO:0045359 9.64 TLR4 TLR9
37 fever generation GO:0001660 9.63 IL1A IL1B
38 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 IL1B IL6 LTF TLR4 TLR9 TNF
39 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
40 positive regulation of NF-kappaB import into nucleus GO:0042346 9.62 IL1B TLR4 TLR9 TNF
41 positive regulation of gene expression GO:0010628 9.61 ERBB2 ERBB3 IL1A IL1B IL6 NGF
42 sequestering of triglyceride GO:0030730 9.6 IL1B TNF
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
44 positive regulation of chemokine production GO:0032722 9.56 IL6 TLR4 TLR9 TNF
45 positive regulation of interleukin-6 production GO:0032755 9.1 IL1A IL1B IL6 TLR4 TLR9 TNF
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 IL1A IL1B IL4 IL6 TLR4 TLR9
47 negative regulation of apoptotic process GO:0043066 10.07 ALB IL4 IL6 LTF NGF

Molecular functions related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL4 IL6 NGF NRTN
2 transmembrane signaling receptor activity GO:0004888 9.55 CD79A ERBB2 ERBB3 TLR4 TLR9
3 cytokine activity GO:0005125 9.35 IL1A IL1B IL4 IL6 TNF
4 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B TLR9

Sources for Keratoconjunctivitis Sicca

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....